ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
EFFICIENCY AND SAFETY OF COMBINING LONG-ACTING AND SHORT-ACTING PDE5 INHIBITORS
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 278301" data-attributes="member: 13851"><p><strong>Introduction</strong></p><p></p><p><em>Erectile dysfunction is a condition that affects many men worldwide, significantly impacting their quality of life. PDE5 inhibitors (PDE5i) are commonly prescribed medications for treating this condition, but some patients do not adequately respond to these treatments.</em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em>This study aims to evaluate the efficacy and safety of a combination of long-acting and short-acting PDE5 inhibitors in non-responding patients.</em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>The study was conducted on 40 men with erectile dysfunction refractory to PDE5 inhibitors. Participants were evaluated using questionnaires, clinical examinations,and paraclinical tests. <strong>All patients received a combination treatment of daily 5 mg tadalafil and 100 mg sildenafil ondemand, one hour before sexual intercourse.</strong> Patients were followed up for 12 weeks, and the results were assessed using questionnaires and recording of side effects.</em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em>The average age of the participants was 47.4 years.The main etiologies of erectile dysfunction were vascular, psychogenic, age-related, or neurological. After 6 weeks of treatment, a statistically significant improvement was observed in erectile function scores (SHIM) and erectile rigidity scores (EHS). This improvement was maintained until the 12th week, although not significantly. Side effects were generally minor and well-tolerated.</em></p><p></p><p></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em><u>The combination of long-acting and short-acting PDE5 inhibitors proved to be effective and safe in nonresponding patients to PDE5 inhibitors</u>. This therapeutic approach offers a promising alternative before resorting to other more invasive options, such as prostaglandins or penile prosthesis. <u>The combined use of these two types of inhibitors improves erectile function while minimizing undesirable side effects</u>. Further studies could explore the addition of vacuum devices, shockwave therapy, or platelet-rich plasma injections to optimize outcomes. <u>Overall, this study provides valuable insights for urologists in the treatment of non-responding patients to a single type of PDE5 inhibitor, opening up new therapeutic perspectives</u>.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 278301, member: 13851"] [B]Introduction[/B] [I]Erectile dysfunction is a condition that affects many men worldwide, significantly impacting their quality of life. PDE5 inhibitors (PDE5i) are commonly prescribed medications for treating this condition, but some patients do not adequately respond to these treatments.[/I] [B]Objective[/B] [I]This study aims to evaluate the efficacy and safety of a combination of long-acting and short-acting PDE5 inhibitors in non-responding patients.[/I] [B]Methods[/B] [I]The study was conducted on 40 men with erectile dysfunction refractory to PDE5 inhibitors. Participants were evaluated using questionnaires, clinical examinations,and paraclinical tests. [B]All patients received a combination treatment of daily 5 mg tadalafil and 100 mg sildenafil ondemand, one hour before sexual intercourse.[/B] Patients were followed up for 12 weeks, and the results were assessed using questionnaires and recording of side effects.[/I] [B]Results[/B] [I]The average age of the participants was 47.4 years.The main etiologies of erectile dysfunction were vascular, psychogenic, age-related, or neurological. After 6 weeks of treatment, a statistically significant improvement was observed in erectile function scores (SHIM) and erectile rigidity scores (EHS). This improvement was maintained until the 12th week, although not significantly. Side effects were generally minor and well-tolerated.[/I] [B]Conclusions [I][U]The combination of long-acting and short-acting PDE5 inhibitors proved to be effective and safe in nonresponding patients to PDE5 inhibitors[/U]. This therapeutic approach offers a promising alternative before resorting to other more invasive options, such as prostaglandins or penile prosthesis. [U]The combined use of these two types of inhibitors improves erectile function while minimizing undesirable side effects[/U]. Further studies could explore the addition of vacuum devices, shockwave therapy, or platelet-rich plasma injections to optimize outcomes. [U]Overall, this study provides valuable insights for urologists in the treatment of non-responding patients to a single type of PDE5 inhibitor, opening up new therapeutic perspectives[/U].[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
EFFICIENCY AND SAFETY OF COMBINING LONG-ACTING AND SHORT-ACTING PDE5 INHIBITORS
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top